About Okairos
Okairos is a Healthcare company based in Basel (Switzerland) founded in 2007, and was acquired by GSK in May 2013. Developer of vaccines against a range of infectious diseases. Okairos has raised $20.53 million across 2 funding rounds from investors including GSK, Life Sciences Partners and Versant Ventures. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral.
Company details
Okairos was founded in 2007 in Basel, Switzerland, within the biotechnology sector focused on infectious diseases. Vaccines are developed targeting malaria and hepatitis C as primary programs, while HIV, Ebola, and respiratory syncytial virus (RSV) initiatives remain in developmental stages. Operations center on advancing these vaccine candidates through research and clinical pathways.
- Headquarters Basel, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website okairos.com
- Social LinkedIn
- Acquired by GSK (May 2013)
Funding Insights of Okairos
Okairos has successfully raised a total of $20.53M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $20.53 million completed in September 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.53M
- Total Rounds 2
- Last Round Series B β $20.53M
- Investors Count 6
All 2 funding rounds of Okairos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2010 | $20.53M | Series B | β | Versant Ventures | |
| Jun 2007 | Seed | β | β |
7 investors in total: 7 institutional.
Investors in Okairos
Okairos has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include GSK, Life Sciences Partners and Versant Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Healthcare investments are targeted by Boehringer Ingelheim Venture Fund. | boehringer-ingelheim-venture.com | |||
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
EQT is recognized as a global investment organization focused on value creation. | eqtgroup.com | |||
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom |
Investor details for Okairos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Okairos
4 dated milestones of Okairos across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Okairos is founded.
- Funding First funding round.
- Funding Latest funding round, Series B, of $20.5M.
- Exit Acquired by GSK.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Okairos
Complete news archive for Okairos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Okairos
Okairos was founded in 2007.
Okairos is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Okairos is a funded company, having raised a total of $20.53M across 2 funding rounds to date.
Okairos was founded in 2007 in Basel, Switzerland, within the biotechnology sector focused on infectious diseases. Vaccines are developed targeting malaria and hepatitis C as primary programs, while HIV, Ebola, and respiratory syncytial virus (RSV) initiatives remain in developmental stages. Operations center on advancing these vaccine candidates through research and clinical pathways.
Okairos has 7 investors. Key investors include GSK, Life Sciences Partners, Versant Ventures, Boehringer Ingelheim Venture Fund, and BioMedPartners.
Yes. Okairos was acquired by GSK in May 2013.

